Nuwellis Trims Q3 Operating Loss by 24% as Gross Margins Reach 70%

Nuwellis Inc. reported a 24% reduction in third-quarter operating loss for 2026, driven by a 430-basis-point expansion in gross margins to 70% and a 13% year-over-year drop in operating expenses. For medical device investors and healthcare observers, the company's cost controls and operational efficiencies showcase progress toward financial stabilization while broadening its cardiorenal therapy footprint. What to watch next: potential regulatory decisions regarding the firm's FDA submission to expand its pediatric patient coverage.

During the first nine months of 2026, the company placed 32 Aquadex consoles, representing an 88% increase from 17 units sold in the corresponding period of the prior year. In the third quarter specifically, console sales stood at eight units compared to 12 in the third quarter of the previous year. Management emphasized that expanding the active console base is crucial for driving ongoing recurring revenue from circuit usage across hospital accounts. Financial management confirmed that the business currently holds a cash runway extending through the second quarter of 2027.

On the clinical and regulatory front, Nuwellis recently submitted a 510(k) application to the U.S. Food and Drug Administration to lower the minimum body weight indication for its Aquadex system. If approved, the shift would allow the platform to serve a broader pediatric patient demographic. Corporate strategy remains focused on driving higher utilization, expanding adult critical care adoption, and leveraging distribution collaborations to scale the platform with minimal capital outlays.